Cargando…
The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
BACKGROUND: BRAF mutations occur in 2–4% non-small cell lung cancer (NSCLC) patients and can be categorized into three functional classes based on signaling mechanism and kinase activity: RAS-independent kinase-activating V600 monomers (class 1), RAS-independent kinase-activating dimers (class 2) an...
Autores principales: | Lin, Quan, Zhang, Haoran, Ding, Huaxin, Qian, Jun, Lizaso, Analyn, Lin, Jing, Han-Zhang, Han, Xiang, Jianxing, Li, Yuping, Zhu, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716889/ https://www.ncbi.nlm.nih.gov/pubmed/31470866 http://dx.doi.org/10.1186/s12967-019-2036-7 |
Ejemplares similares
-
The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients
por: Yang, Li-Bo, et al.
Publicado: (2015) -
Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
por: Ahn, Jun-Ho, et al.
Publicado: (2015) -
Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016) -
Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant
por: Bjorklund, Dennis M., et al.
Publicado: (2022) -
BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)